12:00 AM
Mar 12, 2007
 |  BioCentury  |  Product Development

ESA timeline

ESA timeline

In May 2004, FDA's Oncologic Drugs Advisory Committee concluded that ongoing trials sponsored by Amgen (AMGN) and Johnson & Johnson (JNJ) were likely to address safety concerns about the use of erythropoietin products by cancer patients. The concerns were raised by two large European...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >